Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
22 déc. 2021 09h12 HE
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic, Janssen과 연구, 라이선스, 협력 계약 체결하고 치료용 단백질 신약 후보 제조 위해 C1 플랫폼 공급
17 déc. 2021 18h45 HE
|
Dyadic International, Inc.
미국 플로리다주 주피터, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 글로벌 바이오테크 기업인 Dyadic International, Inc. (NASDAQ: DYAI)은 Johnson & Johnson 산하 Janssen Pharmaceutical Companies에 소속된 Janssen Biotech, Inc.와 연구,...
ダイアディックが、C1プラットフォームを用いた治療用タンパク質候補の製造に関する研究･ライセンス･共同研究契約をヤンセンと締結したことを発表
17 déc. 2021 18h45 HE
|
Dyadic International, Inc.
フロリダ州ジュピタ, Dec. 18, 2021 (GLOBE NEWSWIRE) -- ダイアディック･インターナショナル (Dyadic International, Inc.、以下「ダイアディック」、「同社」) (NASDAQ: DYAI)...
Dyadic宣布与杨森（Janssen）就使用其C1平台生产治疗性蛋白质候选药物达成研究、许可和合作协议
17 déc. 2021 18h45 HE
|
Dyadic International, Inc.
佛罗里达州朱庇特, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 专注于进一步创新、应用和部署其专有C1细胞蛋白质生产平台以针对蛋白质疫苗和疗法加速开发、降低生产成本和提高性能的全球生物技术公司Dyadic International, Inc.（以下简称为“Dyadic”、“我们”、“我们的”或“公司”）（纳斯达克股票代码：DYAI）宣布，公司已与强生（Johnson...
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
17 déc. 2021 07h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
10 nov. 2021 16h00 HE
|
Dyadic International, Inc.
●COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform...
Dyadic Appoints Chief Business Officer to Executive Leadership Team
09 nov. 2021 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
27 oct. 2021 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
10 sept. 2021 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further...
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
11 août 2021 08h35 HE
|
Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...